Clinical trials: Cardiovascular Diseases Risk
Mitral Valve Regurgitation
Mi-thos® Transcatheter Mitral Valve Replacement Study
To evaluate the safety and performance of the Mi-thos® Mitral Heart Valve with the Mi-thos® Transcatheter Delivery System.
- Trial name
- NCT04195984
- Testing
- Mi-thos® valve and transapical delivery system
- Where
- 3 sites in China
- Volunteers
- 122 people
- Sponsor
- Shanghai NewMed Medical Co., Ltd.
Hypertension
IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 (WP2) and Workgroup 1.
- Trial name
- NCT01587742
- Testing
- CCB use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04436029
- Testing
- Descartes 11
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cartesian Therapeutics
Multiple Myeloma
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
- Trial name
- MonumenTAL-8 (NCT06550895)
- Testing
- Cilta-cel, Talquetamab
- Where
- 9 sites in United States, Australia
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Dyslipidemias, Hyperlipidemias
PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT
Dyslipidemias are a major risk factor for the onset of cardiovascular disease, while early diagnosis and appropriate treatment approaches significantly reduce cardiovascular morbidity and mortality.
- Conditions
- Dyslipidemias, Hyperlipidemias, Risk Factor, Cardiovascular, Quality of Life
- Trial name
- PLATINUM (NCT03329729)
- Testing
- Rosuvastatin
- Where
- Greece
- Volunteers
- 4,700 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Disbiosis, Obesity
Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO
This research study aims to determine if a probiotic called Limosilactobacillus fermentum CRL 1446 can improve the health of people at risk for cardiovascular disease.
- Conditions
- Disbiosis, Obesity, Overweight (BMI > 25), Hypertension (Without Type 2 Diabetes Mellitus)
- Trial name
- NCT07530575
- Testing
- Limosilactobacillus fermentum 1446 CRL CONICET 2.20E+9 CFU
- Where
- 2 sites in Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- PINER Pastor Manfredi Winery
Pulmonary Embolism
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care.
- Trial name
- NCT03316729
- Testing
- DS-9231
- Sponsor
- Daiichi Sankyo
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention
Early Feasibility Study of the Supira System in Patients Undergoing HRPCI
The objective of this study is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI.
- Conditions
- Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
- Trial name
- NCT06087575
- Testing
- Supira System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Supira Medical
Cardiovascular Diseases
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective…
- Trial name
- NCT00153101
- Testing
- Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
- Where
- 732 sites in United States, Argentina and 39 more
- Volunteers
- 31,546 people
- Sponsor
- Boehringer Ingelheim
Health, Subjective, Gastrointestinal Dysfunction
Personal Lifestyle Engine (PLX) - Personal Lifestyle Medicine Center (PLMC)
It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory.
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- NCT04007939
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
HIV Infections, Dyslipidemias
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).
- Trial name
- CALIBER (NCT03960541)
- Testing
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Aortic Valve Stenosis
Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study
The purpose of this clinical trial is to evaluate the safety and efficacy of the Prizvalve Pro™ transcatheter aortic valve system in the treatment of patients with severe aortic stenosis who are at high risk of surgery or who are…
- Trial name
- NCT05864456
- Testing
- Prizvalve Pro™ transcatheter aortic valve system
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shanghai NewMed Medical Co., Ltd.
Congestive Heart Failure, Heart Failure
Heart Failure Event Advance Detection Trial
Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing using the Indicor Device.
- Conditions
- Congestive Heart Failure, Heart Failure, Decompensated Heart Failure
- Trial name
- HEADstart (NCT04223271)
- Testing
- Indicor
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Vixiar Medical, Inc.
Hypercholesterolemia
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01507831
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 320 sites in United States, Argentina and 25 more
- Volunteers
- 2,341 people
- Sponsor
- Sanofi
Tricuspid Regurgitation
Early Phase Study Using the 'Pivot Extend' System as a Treatment for Patients With Tricuspid Regurgitation
Participants with severe tricuspid regurgitation may require heart surgery to repair or replace the tricuspid valve. However, there is a high risk associated with these surgeries and it is often not feasible for elderly patients…
- Trial name
- SPACER (NCT07172477)
- Testing
- Pivot Extend
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Tau Medical Australia Pty Ltd
Arterial Hypertension
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
- Trial name
- NCT01071681
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291)
- Where
- France
- Volunteers
- 1,589 people
- Sponsor
- Bayer
Coronary Artery Disease, High Bleeding Risk Patients
ULTRA LONG: BioFreedom Ultra
The goal of this Prospective, multi-center, open-label single-arm study is to Assess the Safety and Effectiveness of additional sizes of the BioFreedom Ultra CoCr Biolimus A9 coated coronary stent system in Patients at high risk…
- Trial name
- NCT05643430
- Testing
- BioFreedom Ultra
- Where
- 9 sites in France, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Biosensors Europe SA
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
This was a placebo-controlled, double-blind, randomized trial in Japanese participants with history of coronary artery disease (CAD) or participants categorized in 'high risk' by JAS 2017 guideline, or Japanese participants with…
- Trial name
- ORION-15 (NCT04666298)
- Testing
- Inclisiran sodium
- Where
- 42 sites in Japan
- Volunteers
- 312 people
- Sponsor
- Novartis Pharmaceuticals
Infant Formula, Growth
Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease
The primary objective of this study is to investigate if consumption of lower protein formula can slow the rate of weight gain of formula-fed infants between 3 and 12 months of age.
- Trial name
- BabyGrowth (NCT03456934)
- Testing
- Modified infant formula, Standard infant formula
- Where
- United Kingdom
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Intensive Care Unit, Coronary Artery Bypass Grafting (CABG)
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight…
- Conditions
- Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
- Trial name
- MODIFY CSX (NCT06279793)
- Testing
- Fish Oil, Intravenous 0.9% Sodium Chloride
- Where
- 10 sites in Germany
- Volunteers
- 550 people
- Sponsor
- GCP-Service International West GmbH